Revenue from Contracts with Customers |
6 Months Ended |
|---|---|
Jun. 30, 2025 | |
| Revenue from Contract with Customer [Abstract] | |
| Revenue from Contracts with Customers | Note 4 — Revenue from Contracts with Customers
Revenue Recognized
In the three and six months ended June 30, 2025, the Company recognized revenue of $1,163 and $1,991, respectively, resulting from the delivery of patient EsoGuard test results. Revenue recognized from customer contracts deemed to include a variable consideration transaction price is limited to the unconstrained portion of the variable consideration. The Company’s revenue for the three and six months ended June 30, 2024 was $976 and $1,977, respectively, resulting from the delivery of patient EsoGuard test results.
Cost of Revenue
The cost of revenues principally includes the costs related to the Company’s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties.
In the three and six months ended June 30, 2025, the cost of revenue was $1,563 and $3,114, respectively, primarily related to costs for our laboratory operations and EsoCheck device supplies. The Company’s cost of revenue for the three and six months ended June 30, 2024 was $1,614 and $3,269, respectively, primarily related to costs for our laboratory operations and EsoCheck device supplies.
|